1例阿来替尼致ALK阳性NSCLC患者罕见不良反应的药学监护

杜中英; 郑兆红; 魏亮; 侯秋雨

doi:10.6039/j.issn.1001-0408.2024.02.22

您当前的位置：

首页 >

文章列表页 >

1例阿来替尼致ALK阳性NSCLC患者罕见不良反应的药学监护

药师与药学服务 | 更新时间：2024-01-24

- 1例阿来替尼致ALK阳性NSCLC患者罕见不良反应的药学监护
- Pharmaceutical care for rare ADR in a patient with ALK-positive non-small cell lung cancer induced by alectinib
- 中国药房 2024年35卷第2期页码：247-250
- 作者机构：
  
  1.青岛市第八人民医院药学部，山东青岛　266100
  2.青岛市第八人民医院心胸外科，山东青岛　266100
- 作者简介：
  
  主管药师，硕士。研究方向：肿瘤药物合理应用。电话：0532-87627411。E-mail：duzhongying1017@126.com
  主任医师，硕士。研究方向：胸部肿瘤的诊断和治疗。电话：0532-87627506。E-mail：houqiuyu@163.com
- 基金信息：
  
  青岛市医药卫生科研计划项目(2023-WJZD094;2021-WJZD113)
- DOI：10.6039/j.issn.1001-0408.2024.02.22
  中图分类号： R969.3
- 纸质出版日期：2024-01-30，
  
  收稿日期：2023-08-15，
  
  修回日期：2023-12-05，
扫描看全文
杜中英,郑兆红,魏亮等.1例阿来替尼致ALK阳性NSCLC患者罕见不良反应的药学监护 ^Δ[J].中国药房,2024,35(02):247-250.

DU Zhongying,ZHENG Zhaohong,WEI Liang,et al.Pharmaceutical care for rare ADR in a patient with ALK-positive non-small cell lung cancer induced by alectinib[J].ZHONGGUO YAOFANG,2024,35(02):247-250.
杜中英,郑兆红,魏亮等.1例阿来替尼致ALK阳性NSCLC患者罕见不良反应的药学监护 ^Δ[J].中国药房,2024,35(02):247-250. DOI： 10.6039/j.issn.1001-0408.2024.02.22.

DU Zhongying,ZHENG Zhaohong,WEI Liang,et al.Pharmaceutical care for rare ADR in a patient with ALK-positive non-small cell lung cancer induced by alectinib[J].ZHONGGUO YAOFANG,2024,35(02):247-250. DOI： 10.6039/j.issn.1001-0408.2024.02.22.

摘要

目的

为间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌（NSCLC）患者的安全用药提供参考。

方法

临床药师参与1例ALK阳性NSCLC患者服用阿来替尼后，出现双侧胸腔积液并发溶血性贫血的诊治过程。针对患者胸腔积液、溶血性贫血等症状，临床药师排查患者的既往用药史和疾病史，以及可能存在药物相互作用的因素；同时根据患者服用阿来替尼与胸腔积液和溶血性贫血的时间相关性，建议停用阿来替尼，待患者相关症状改善后，建议减量使用阿来替尼。但该患者再次出现双侧胸腔积液和溶血性贫血，临床药师根据诺氏评估量表评估阿来替尼与双侧胸腔积液、溶血性贫血的相关性后，建议永久停用阿来替尼，并与临床医生共同建议患者更换为恩沙替尼。

结果

临床医生采纳临床药师的建议。换药后，该患者的胸腔积液消退，溶血性贫血症状改善。阿来替尼与双侧胸腔积液、溶血性贫血的相关性均为“确定”。

结论

临床药师通过参与ALK阳性NSCLC患者的药学监护，协助临床医生制定个体化用药方案，保障了患者用药的安全性。

Abstract

OBJECTIVE

To provide reference for safe drug use in patients with anaplastic lymphoma kinase （ALK）-positive non-small cell lung cancer （NSCLC）.

METHODS

Clinical pharmacists participated in the diagnosis and treatment of a patient with ALK-positive NSCLC who developed bilateral pleural effusion and hemolytic anemia after taking alectinib； regarding symptoms such as pleural effusion and hemolytic anemia in the patient， clinical pharmacists investigated the patient’s history of medication and disease， as well as potential drug interaction； to consider the correlation between the patient’s use of alectinib and the duration of pleural effusion and hemolytic anemia， clinical pharmacists suggested that clinical doctors discontinued alectinib and used reduced dose treatment after the pleural effusion improved， but the patient suffered from bilateral pleural effusion and hemolytic anemia again； after evaluating the correlation between alectinib and bilateral pleural effusion and hemolytic anemia using the Naranjo’s assessment scale， clinical pharmacists recommend permanent discontinuation of alectinib and jointly recommend replacement with ensartinib with clinical physicians.

RESULTS

Physicians adopted the suggestions of clinical pharmacists. The pleural effusion subsequently regressed and hemolytic anemia improved after replacing the drug. The correlation between alectinib and bilateral pleural effusion and hemolytic anemia was confirmed.

CONCLUSIONS

Clinical pharmacists participate in pharmaceutical monitoring of ALK-positive NSCLC patients， assist clinical doctors in developing personalized medication recommendations， and ensure the safety of patient medication.

关键词

阿来替尼胸腔积液溶血性贫血药学监护

Keywords

pleural effusionhemolytic anemiapharmaceutical care

references

DU X，SHAO Y，QIN H F，et al. ALK-rearrangement in non-small-cell lung cancer（NSCLC）[J]. Thorac Cancer，2018，9（4）：423-430.

ZHOU C C，KIM S W，REUNGWETWATTANA T，et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer（ALESIA）：a randomised phase 3 study[J]. Lancet Respir Med，2019，7（5）：437-446.

齐冉，高胜男，刘旭婷，等. 间变性淋巴瘤激酶阳性非小细胞肺癌治疗药物经济性的系统评价[J]. 中国药房，2022，33（11）：1368-1373.

QI R，GAO S N，LIU X T，et al. Systematic review of the economical efficiency of drugs for anaplastic lymphoma kinase-positive non-small cell lung cancer [J]. China Pharm，2022，33（11）：1368-1373.

PAIK J，DHILLON S. Alectinib：a review in advanced，ALK-positive NSCLC[J]. Drugs，2018，78（12）：1247-1257.

ULHOI M P，SORENSEN B S，MELDGAARD P. Alectinib-induced pleural and pericardial effusions in ALK-positive NSCLC[J]. Case Rep Oncol，2021，14（3）：1323-1327.

OKUMOTO J，SAKAMOTO S，MASUDA T，et al. Alectinib-induced immune hemolytic Anemia in a patient with lung adenocarcinoma[J]. Intern Med，2021，60（4）：611-615.

EL SAYED R，TEHFE M，BLAIS N. Successful treatment with brigatinib after alectinib-induced hemolytic anemia in patients with metastatic lung adenocarcinoma：a case series[J]. Curr Oncol，2022，30（1）：518-528.

MISAWA K，NAKAMICHI S，IIDA H，et al. Alectinib-induced severe hemolytic anemia in a patient with ALK-positive non-small cell lung cancer：a case report[J]. Onco Targets Ther，2023，16：65-69.

DORES G M，NAYERNAMA A，CHENG C，et al. Hemoly-tic anemia following alectinib reported to the U.S. Food and Drug Administration Adverse Event Reporting System[J]. Am J Hematol，2022，97（4）：E129-E132.

LEE C S，SULLIVAN K. Alectinib-induced hemolytic anemia[J]. J Oncol Pharm Pract，2023，29（5）：1251-1254.

YUAN Y，MAPP S，XU W. Two cases of marked red cell anisopoikilocytosis and haemolysis with alectinib，an anaplastic lymphoma kinase inhibitor[J]. Br J Haematol，2020，190（5）：642.

AERTS R，BRIJS J，VAN NIEUWENHUYSE T，et al. Hemolytic anemia caused by alectinib，an anaplastic lymphoma kinase（ALK）inhibitor：a case report[J]. Curr Probl Cancer Case Rep，2022，7：100176.

GULLAPALLI V，XU W，LEWIS C R，et al. A multi-centre case series of alectinib-related erythrocyte membrane changes and associated haemolysis[J]. J Hematop，2021，14（2）：131-136.

HE J X，SU C X，LIANG W H，et al. Icotinib versus chemotherapy as adjuvant treatment for stage Ⅱ-ⅢA EGFR-mutant non-small-cell lung cancer（EVIDENCE）：a randomised，open-label，phase 3 trial[J]. Lancet Respir Med，2021，9（9）：1021-1029.

WU Y L，TSUBOI M，JOHN T，et al. A plain language summary of results from the ADAURA study：osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer[J]. Future Oncol，2021，17（35）：4827-4835.

NARANJO C A，BUSTO U，SELLERS E M，et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther，1981，30（2）：239-245.

孔宪彬，任永慧，孔宪彩. 泮托拉唑的不良反应及与其他药物的相互作用[J]. 中国实用医药，2023，18（17）：133-135.

KONG X B，REN Y H，KONG X C. Adverse reactions of pantoprazole and interactions with other drugs[J]. China Pract Med，2023，18（17）：133-135.

ZHAO D H，CHEN J，CHU M M，et al. Pharmacokinetic-based drug-drug interactions with anaplastic lymphoma kinase inhibitors：a review[J]. Drug Des Devel Ther，2020，14：1663-1681.

SCHEEN A J. Clinical pharmacokinetics of metformin[J]. Clin Pharmacokinet，1996，30（5）：359-371.

DHALIWAL G，CORNETT P A，JR TIERNEY L M. Hemolytic anemia[J]. Am Fam Physician，2004，69（11）：2599-2606.

国家卫生健康委员会. 自身免疫性溶血性贫血诊疗指南：2022年版[J]. 全科医学临床与教育，2022，20（5）：388-390.

The National Health Commission Diagnosis and treatment of autoimmune hemolytic anemia：2022 edition[J]. Clin Educ Gen Pract，2022，20（5）：388-390.

PETERS S，CAMIDGE D R，SHAW A T，et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer[J]. N Engl J Med，2017，377（9）：829-838.

LAVALLADE H D，KHODER A，HART M，et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling[J]. Blood，2013，122（2）：227-238.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

1例鹦鹉热衣原体重症肺炎患者的抗感染治疗及药学监护

1例类鼻疽脓毒症患者的全程个体化药学监护

临床药师参与1例EB病毒性脑炎患者的药学实践

临床药师参与1例PCI术后合并急性心力衰竭患者的药学监护

1例复杂性静脉血栓栓塞症合并急性肾功能不全患者的抗凝药物治疗管理